<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31765">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02693158</url>
  </required_header>
  <id_info>
    <org_study_id>IP-15-002</org_study_id>
    <nct_id>NCT02693158</nct_id>
  </id_info>
  <brief_title>The Direct III Post Market Study</brief_title>
  <acronym>Direct III</acronym>
  <official_title>Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Svelte Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Svelte Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this multicenter, single-arm, observational study is to evaluate
      the feasibility of a systematic direct stenting strategy with the Svelte SLENDER IDS
      Sirolimus-Eluting Coronary Stent-on-a-Wire Integrated Delivery System (SLENDER IDS) in an
      all-comers, real-world population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this post-market study, the population will include real-world subjects who are intended
      to be treated, with SLENDER IDS as standard therapy. Follow-up contacts post procedure will
      be made for clinical assessments at hospital discharge, 1, 6 and 12 months.

      This study is designed as a prospective, multi-center, single-arm, observational all-comers
      clinical study to collect ongoing safety and efficacy of SLENDER IDS and to determine the
      feasibility of a direct stenting strategy in an all-comers population. A minimum of two
      hundred fifty (250) subjects will be treated at up to 20 sites in Europe.

      Review of safety data and risks to subjects will be monitored by an independent Clinical
      Events Committee (CEC) at pre-specified enrollment milestones.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>Discharge, 1, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>Discharge, 1, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study is designed as a prospective, multi-center, single-arm, observational
        all-comers clinical study to collect ongoing safety and efficacy of SLENDER IDS and to
        determine the feasibility of a direct stenting strategy in an all-comers population.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is â‰¥ 18 years old;

          2. Subject has symptomatic heart disease due to coronary artery lesions of length &lt; 28
             mm and a reference vessel diameter 2.5 - 4.0 mm.

          3. Subject is intended to be treated with PCI and implantation of SLENDER IDS as part of
             his/her standard treatment

          4. Subject or subject's legal representative understands the study requirements and the
             treatment procedures and provides written informed consent before any study specific
             tests or procedures are performed.

        Exclusion Criteria:

          1. Subject is unable to receive anti-platelet and/or anti-coagulant therapy;

          2. Subject is allergic to sirolimus, PEA III Ac Bz, cobalt, chromium, nickel or
             tungsten;

          3. The subject is judged to have lesions preventing complete inflation of an angioplasty
             balloon or proper placement of a coronary stent, including chronic total occlusions.

          4. Subject is a woman who is pregnant or nursing (a pregnancy test must be performed
             within 7 days prior to the index procedure in women of child-bearing potential, based
             on the standard of care for the cath lab);

          5. Subject is participating in another investigational drug or device clinical trial
             that the investigator feels would interfere with the subject's participation in this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Donohoe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Svelte Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betsy Lowry, CCRP</last_name>
    <phone>9082642181</phone>
    <email>blowry@sveltemedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Sturges</last_name>
    <phone>9083798897</phone>
    <email>psturges@sveltemedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meander Medical Center</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Van Doorn</last_name>
      <email>jl.van.doorn@meandermc.nl</email>
    </contact>
    <investigator>
      <last_name>BJB Hamer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannette Schoep</last_name>
      <email>j.j.m.schoep@olvg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lizbeth Janzen</last_name>
      <email>e.m.janzen@olvg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Gioanni Amoroso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooi Hospital</name>
      <address>
        <city>Blaircum</city>
        <zip>1261AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirjam van der Zeijst</last_name>
      <email>mailto:mvanderzeijst@tergooi.nl</email>
    </contact>
    <investigator>
      <last_name>Ferdinand Kiemeneij, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marijke Kruijs Voorberge-Baas</last_name>
      <email>mbaas@amphia.nl</email>
    </contact>
    <investigator>
      <last_name>Martijn Meuwissen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer Hospital</name>
      <address>
        <city>Dordrecht</city>
        <zip>3300 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther deJong</last_name>
      <email>e.salentijn@asz.nl</email>
    </contact>
    <contact_backup>
      <last_name>Wouter Lansink</last_name>
      <email>w.lansink@asz.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Sander Ijsselmuiden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Antonius Hospital</name>
      <address>
        <city>Nieuwegin</city>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Bras</last_name>
      <email>r.bras@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Pierfrancesco Agostoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Breuer-Otten</last_name>
      <phone>31 88 75 594 52</phone>
      <email>y.breuer@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Pieter Stella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>February 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
